Jean-Charles Soria to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Jean-Charles Soria has written about Clinical Trials, Phase I as Topic.
Connection Strength
2.535
-
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? Eur J Cancer. 2020 09; 137:235-239.
Score: 0.740
-
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. Eur J Cancer. 2017 09; 83:185-193.
Score: 0.600
-
SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol. 2021 03; 22(3):298-301.
Score: 0.192
-
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? Br J Cancer. 2018 10; 119(8):937-939.
Score: 0.164
-
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
Score: 0.158
-
Are phase I trials safe for older patients? J Geriatr Oncol. 2018 03; 9(2):87-92.
Score: 0.151
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.151
-
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
Score: 0.151
-
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs. 2017 06; 28(5):540-545.
Score: 0.149
-
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
Score: 0.041
-
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
Score: 0.039